Galvanize is a leader in energy-based medical device technology that impacts biologic processes. With its innovative Aliya platform, the company is initially focused on chronic bronchitis, cardiac arrhythmias, oncology, and drug delivery. Galvanize is dedicated to transforming energy into therapy.
News
Galvanize Therapeutics, Inc.
1531 Industrial Road
San Carlos, CA 94070 USA
© 2022 Galvanize Therapeutics, Inc. All rights reserved.
© 2022 Galvanize Therapeutics, Inc.
All rights reserved.
Steve Anheier
Chief Financial Officer
Steve is Chief Financial Officer at Galvanize. He brings a proven history of driving growth in revenue and profitability. Most recently, Steve was CFO of Vocera Communications, a publicly traded healthcare IT company focused on clinical communication and collaboration, which was acquired by Stryker Corporation for $3.1 billion. Steve was internally promoted into the CFO position at Vocera from his role as Vice President of Finance & Accounting. Prior to Vocera, Steve served in various roles of increasing responsibility for Accuray Incorporated in Strategic Finance and Investor Relations. He started his career at KPMG where he received his CPA and holds a bachelor’s degree in accounting from California Polytechnic State University San Luis Obispo
Michael Iversen
Senior Vice President, Sales & Marketing, Electrophysiology
Michael is Senior Vice President of Sales & Marketing, Electrophysiology. He brings to Galvanize more than 20 years of commercial experience in the Electrophysiology market. He most recently served as Chief Commercial Officer at Acutus Medical and previously worked in various leadership positions at Biotronik, Boston Scientific and Guidant. He holds an MBA from the University of Michigan and a bachelor’s degree in Economics from Copenhagen Business School.
Mohit Trikha, PhD
Venture Partner, ATP
Mohit (Mo) Trikha is a venture partner at ATP. Prior to ATP, Mo was vice president and head of Oncology Early Development at AbbVie and the site head of AbbVie Bay Area. At AbbVie, he was accountable for advancing oncology discovery stage programs up to clinical proof of concept. He was a core member of oncology business development committees, chaired AbbVie’s Oncology Early Development Review Committee, and led multiple external collaborations. Prior to AbbVie, Mo was president, chief scientific officer, and head of Triphase Accelerator and served on the Triphase board. Prior to Triphase, Mo worked at Genentech, Ambit and Centocor/Johnson & Johnson in various roles in R&D. Over his 20 years of drug discovery and development experience, he has helped develop multiple cancer medicines and contributed to advancing more than 30 oncology programs from discovery to clinical trials. Mo received his BS from California State University, Los Angeles and his PhD from the University of Southern California.
Seth Harrison, MD
Founder and Managing Partner, ATP
Seth Harrison is founder and managing partner of ATP (Apple Tree Partners), a leading life sciences venture capital firm. Seth began investing in life sciences in 1991 as a venture partner at Sevin Rosen Funds and went on to be a general partner at Oak Investment Partners before starting ATP in 1999. Some of his earlier investments include Aileron Therapeutics, Akero Therapeutics, ArQule, Chinook Therapeutics, Coelacanth, Corvidia Therapeutics, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare, Informed Access, SGX Pharmaceuticals, Stoke Therapeutics, Syntimmune, Tendyne, Ultracision, and ViroPharma. Seth currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the boards of the 15 portfolio companies created within ATP’s current fund to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s health and HIV prevention. Seth received an AB from Princeton University and an MD and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.
Anna Batarina, CFA
Partner, ATP
Anna Batarina is a partner at ATP (Apple Tree Partners), a leading life sciences venture capital firm. She joined ATP in 2016 from Braeburn, an ATP portfolio company, where she served as vice president of Strategic Development. Before Braeburn, she was a member of the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to that, she was senior vice president and head of Capital Markets and Investor Relations at Uralkali, a leading global agrochemical business, where she led one of the most successful IPOs on the London Stock Exchange. Anna received an MA in Global Affairs (Global Health track) and a graduate certificate in Global Health, Public Health from Yale University. She holds an MS in clinical psychology from Lomonosov Moscow State University, a BS in finance from Financial University under the Government of the Russian Federation, and a CFA charter.
Doug Godshall (Chair)
President and CEO, Shockwave Medical
Doug Godshall, chair of the Board of Directors of Galvanize Therapeutics, is currently president, CEO, and a director of Shockwave Medical, a leading medical device company focused on developing and commercializing products for the treatment of calcified cardiovascular disease. He is the former CEO and Director of HeartWare, an innovator in LVAD acquired by Medtronic in 2016 for $1.1B. Prior to HeartWare, Doug held executive and leadership positions at Boston Scientific, including president of the Vascular Surgery Division, member of the Operating Committee and vice president of Business Development. Doug also serves on the Board of Saluda Medical and served on the board of Gala Therapeutics before it merged into Galvanize Therapeutics. He earned an MBA from Northeastern University and a BA in Economics from Lafayette College.
Steve Ricottone
Vice President, Global Market Development
Steve is vice president of Global Market Development for the airway/COPD division of Galvanize Therapeutics. In this role, he leads commercial development activities for RheOx globally. Steve is a healthcare executive with more than 15 years of successful healthcare management experience in sales, marketing, and market development, with a focus on developing markets for breakthrough technologies internationally. Steve joined Galvanize Therapeutics from Pulmonx, a global leader in interventional pulmonology that he joined at a very early stage and left post IPO (NASDAQ; LUNG) and where he was vice president of Marketing and Market Development. Previously, Steve held various sales and marketing management roles at Baxter, Zimmer, and Bayer. Steve holds a bachelor’s degree in Physiotherapy from the University of Brussels (Belgium) and a Master of Business Administration (MBA) from the Open University, Milton Keynes (UK).
Michael Iversen
Vice President, Business Development and Commercial Strategy
Michael is Vice President of Business Development and Commercial Strategy. He brings to Galvanize more than 20 years of commercial experience in the Electrophysiology market. He most recently served as Chief Commercial Officer at Acutus Medical and previously worked in various leadership positions at Biotronik, Boston Scientific and Guidant. He holds an MBA from the University of Michigan and a bachelor’s degree in Economics from Copenhagen Business School.
Bill Green
Senior Vice President, Sales & Marketing, Oncology
Bill serves as senior vice president of Sales & Marketing, Oncology, for Galvanize. Bill has been a part of the thoracic oncology and interventional oncology space since 2004. He has led early commercial teams at medical device startups, such as superDimension (acquired by Covidien/Medtronic in 2012), NeuWave Medical (acquired by Johnson & Johnson in 2015), and most recently at Auris Health, where he was the vice president of Sales. Auris was acquired by Johnson & Johnson for $3.4 billion in 2019, one of the largest pre-IPO medical device company acquisitions to date. Bill has a bachelor’s degree in Business Finance from Duquesne University.
William S. Krimksy, MD, FCCP, DAABIP
Chief Medical Officer
William Krimsky is Chief Medical Officer of Galvanize Therapeutics. Bill has been a pioneer in the Interventional Pulmonology space for more than 20 years, carving an innovative pathway for the treatment of lung diseases. In 2015, he co-invented the RheOx technology with Jonathan Waldstreicher to continue his focus on therapeutic intervention in the pulmonary and oncology field. Bill earned his medical degree at the University of Pittsburgh School of Medicine and completed an internship at Mercy Hospital and a residency at Johns Hopkins University/Sinai Hospital. Following that, he was a fellow in pulmonary and critical care medicine at Dartmouth-Hitchcock Medical Center and a visiting fellow in Interventional Pulmonology at the Hospital of the University of Pennsylvania. He is the author of multiple publications.
James Stambaugh
Senior Vice President, Clinical Affairs
James is senior vice president of Clinical Affairs for Galvanize. He has over 25 years of experience in medical device and pharmaceutical development, from early-stage start-ups to large, established corporations, and has been responsible for over 35 clinical trials from FIH to pivotal phase III. Prior to joining Galvanize, James was senior vice president of Clinical Affairs at Intersect ENT, where he played a central role in taking the company from inception and concept stage in 2006, through several rounds of VC financing, to an IPO in 2014. Prior to that, James served as director, of Clinical Operations for Guidant’s Vascular Intervention division (acquired by Abbott in 2006), responsible for conduct of clinical studies for embolic protection, coronary stents, and drug-eluting stents. James started his career as an analytical chemist at an ophthalmic pharmaceutical company, InSite Vision. He holds a B.S. in Chemistry from the University of California at Davis.
Deb Sheffield
Senior Vice President, Regulatory and Quality Affairs
Deborah Sheffield is senior vice president of Quality and Regulatory Affairs at Galvanize. She is an experienced professional in the design and development of innovative products, with over 25 years of experience in and understanding of the global regulatory environment in the medical device field. She has successfully obtained US and International medical device approvals for clinical studies and market clearance/approvals for Class I, II and III devices in markets including US, Canada, Australia, South America, India and Europe. Her technology experience encompasses a variety of medical devices platforms, including energy-based therapies (RF, laser, ultrasound, IRE), active implantables, and IVD devices for disease states including neuro, pulmonary, GI and cardiac functions.
Deb has previously held several key leadership positions at companies including Johnson & Johnson and at several start-up companies including Northstar Neuroscience (IPO and subsequently acquired by St. Jude Medical). She holds a BS from Kettering University in Industrial Manufacturing Engineering and a MS from Oakland University in Applied Statistics. She also attended the University of Cincinnati Nursing School with a focus on clinical research.
Kevin Taylor
Chief Operating Officer
Kevin brings to Galvanize nearly three decades of medical device development, operational experience, and industry leadership. His device development experience spans a range of applications, including joint replacement, cardiovascular intervention, ear nose and throat therapies, and therapeutic energy delivery systems. Kevin also has extensive operational experience in pre-commercial and commercial organizations and has held key management positions in companies including Gala Therapeutics, ReCor Medical, Acclarent, and Guidant (now part of Boston Scientific). Kevin earned his mechanical engineering degree at Drexel University and received his MBA degree from the University of Chicago.
Jonathan Waldstreicher, MD
Founder and Chief Executive Officer
Jonathan is founder and CEO of Galvanize Therapeutics. He has worked in medical devices as an entrepreneur,
investor, and clinician. Jon was previously a partner on the MedTech team at ATP, the life sciences venture capital
firm where he founded Gala Therapeutics in 2015 and Galaxy Medical in 2020, both of which were merged into
Galvanize Therapeutics in 2022. Prior to joining ATP, Jon was a director of Global Surgery R&D at Johnson &
Johnson. He started at J&J as an associate director in the Corporate Office of Science & Technology. Before medical
school, Jon worked in equity research at Bear Stearns. Jon received a BA from Brandeis University in economics
and an MD and MBA from Tufts University School of Medicine. He completed a general surgery internship at Tufts
Medical Center in Boston.